Marius Pharmaceuticals Applauds FDA’s Proposed Testosterone Labeling Updates as a Turning Point for Men’s Health

The FDA’s second major labeling update in 16 months — after its February 2025 removal of the cardiovascular boxed warning — marks a historic modernization of how testosterone therapy is prescribed, bringing labeling in step with a decade of new clinical evidence. Marius CEO Shalin Shah, an invited speaker at the agency’s expert panel on the therapy, helped advance the earlier change.